HEPION PHARMACEUTICALS INC. - COMMON STOCK

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

22 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

11 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

02 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

11 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

04 9 2024 09:25:00 提供 Nasdaq GlobeNewswire

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

22 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

19 4 2024 16:30:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

06 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

16 2 2024 08:00:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals to Present at NASH-TAG 2024

03 1 2024 17:15:00 提供 Nasdaq GlobeNewswire

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

07 12 2023 08:00:00 提供 Nasdaq GlobeNewswire